StockNews.AI
GMED
StockNews.AI
21 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims 0n Behalf of Investors of Globus Medical, Inc. - GMED

1. Pomerantz LLP is investigating potential securities fraud at Globus Medical. 2. Globus Medical's Q1 2025 earnings missed estimates, impacting stock price significantly. 3. The company's revenue declined year-over-year by 1.4%, raising investor concerns. 4. Stock fell nearly 23% following the disappointing earnings announcement. 5. Investors have been advised to join the class action against the company.

4 mins saved
Full Article

FAQ

Why Bearish?

Negative earnings report and a significant stock price drop indicate investor concern. Historical investor reactions to missed earnings can further depress stock prices.

How important is it?

Legal investigations can lead to long-term ramifications for a company's reputation and stock value, affecting GMED's share price.

Why Short Term?

Immediate investor sentiment is affected, likely resulting in continued volatility. If issues resolve, recovery might happen, but currently, sentiment is negative.

Related Companies

SPYMDTSYKZBH
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, Globus issued a press release reporting its financial results for the first quarter of 2025.  Among other items, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, missing consensus estimates by $27.78 million and representing a 1.4% year-over-year decline.  Globus’s President and Chief Executive Officer said that the Company’s “first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders[.]”  On this news, Globus’s stock price fell $16.64 per share, or 22.96%, to close at $55.82 per share on May 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News